Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

MannKind Corp

MNKD ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$4.06

▲ +2.53%

Market Cap $1.31B · Vol 597.74K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$1.31B

Small Cap

Div Yield

N/A

EPS Growth

-1,012.50%

YoY

RSI (14)

55.52

Momentum

Beta

1.08

vs Market

52W High

$6.51

37.63% below

52W Low

$2.23

82.06% above

Volume

597.74K

Avg 1.06M

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

96.40%

Public shares

Shariah Compliance8 STANDARDS

✗ MannKind Corp (MNKD) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MNKD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.78%

+2.53%

+15.34%

+37.63%

YTD

-28.40%

-23.97%

-11.35%

-13.98%

Financials & Valuation

TTM · Annual

Total Revenue	$348.97M
Net Income	$5.86M
Revenue Growth (YoY)	+42.92%
Gross Margin	76.64%
Operating Margin	16.32%
Net Profit Margin	1.68%
ROE	N/A
ROA · ROIC	0.24% · 42.73%

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	-3.76
P/S	5.10
P/B	N/A
P/FCF	130.11
EPS Growth	-1,012.50%
Outstanding Shares	321.54M

Technical Indicators

50-Day SMA	$4.04
200-Day SMA	$4.16
RSI (14)	55.52
Beta	1.08
52-Week High	$6.51
52-Week Low	$2.23

Volume Today	597.74K
Avg Daily Volume (30D)	1.06M
Relative Volume	0.57x
Volatility (10D)	29.31
Volatility (30D)	54.91
Free Float	96.40%

Analyst Consensus

BUY

Current Price $4.06

Mean Target $7.97

52W Low$2.23 52W High$6.51

Current

Target

$2.23 $6.51

Current Analyst target

+96.27% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SLLLY3

ISINUS56400P7069

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.57% ARGX.BR argenx SE -2.06% ARGX argenx SE -1.93% INSM Insmed Inc -0.31% 2269.HK WuXi Biologics (Cayman) Inc -3.00%

Company Profile

MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).